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AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Both health insu ance status and race ind p ndently impact colon cancer (CC) care delivery
and outcomes. The relative importance of these factors in explaining racial and insurance
disparities is less clear, however. This study aimed to determine the association and interac-
tion of race and insurance with CC treatment disparities.
Study setting
Retrospective cohort review of a prospective hospital-based database.
Methods and findings
In this cross-sectional study, patients diagnosed with stage I to III CC in the United States
were identified from the National Cancer Database (NCDB; 2006 to 2016). Multivariable
regression with generalized estimating equations (GEEs) were performed to evaluate the
association of insurance and race/ethnicity with odds of receipt of surgery (stage I to III) and
adjuvant chemotherapy (stage III), with an additional 2-way interaction term to evaluate for
effect modification. Confounders included sex, age, median income, rurality, comorbidity,
and nodes and margin status for the model for chemotherapy. Of 353,998 patients included,
73.8% (n = 261,349) were non-Hispanic White (NHW) and 11.7% (n = 41,511) were non-
Hispanic Black (NHB). NHB patients were less likely to undergo resection [odds ratio (OR)
0.66, 95% confidence interval [CI] 0.61 to 0.72, p < 0.001] or to receive adjuvant chemother-
apy [OR 0.83, 95% CI 0.78 to 0.87, p < 0.001] compared to NHW patients. NHB patients
with private or Medicare insurance were less likely to undergo resection [OR 0.76, 95% CI
0.63 to 0.91, p = 0.004 (private insurance); OR 0.59, 95% CI 0.53 to 0.66, p < 0.001 (Medi-
care)] and to receive adjuvant chemotherapy [0.77, 95% CI 0.68 to 0.87, p < 0.001 (private
insurance); OR 0.86, 95% CI 0.80 to 0.91, p < 0.001 (Medicare)] compared to similarly
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insured NHW patients. Although Hispanic patients with private and Medicare insurance
were also less likely to undergo surgical resection, this was not the case with adjuvant che-
motherapy. This study is mainly limited by the retrospective nature and by the variables pro-
vided in the dataset; granular details such as continuity or disruption of insurance coverage
or specific chemotherapy agents or dosing cannot be assessed within NCDB.
Conclusions
This study suggests that racial disparities in receipt of treatment for CC persist even among
patients with similar health insurance coverage and that different disparities exist for differ-
ent racial/ethnic groups. Changes in health policy must therefore recognize that provision of
insurance alone may not eliminate cancer treatment racial disparities.
Author summary
Why was this study done?
• Patients of Black and Hispanic race and ethnicity have a higher incidence of colon can-
cer (CC), are diagnosed with more advanced disease, and have poorer survival than
White patients.
• Patients with Medicaid insurance and those without insurance also present with more
advanced disease and have poorer outcomes.
• The role of insurance status in explaining these racial disparities is not well understood.
What did the researchers do and find?
• We identified patients diagnosed with stage I to III CC within the National Cancer
Database (NCDB) from 2006 to 2016.
• We investigated factors associated with receiving surgical removal of the cancer as well
as chemotherapy after resection.
• We found that Black patients were less likely to undergo surgical removal and receive
chemotherapy, and Hispanic patients were less likely to undergo surgical removal con-
trolling for insurance type.
• We also found that patients with Medicaid and those without insurance also were less
likely to undergo surgical removal and receive chemotherapy.
• We also found that even in patients with private and Medicare insurance, those that
were Black or Hispanic were less likely to undergo surgical removal and that those that
were Black also were less likely to receive chemotherapy after removal.
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from the National Cancer Database (https://www.
facs.org/quality-programs/cancer/ncdb).
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American Joint Commission on Cancer; CC, colon
cancer; CI, confidence interval; CoC, Commission
on Cancer; GEE, generalized estimating equation;
MIS, minimally invasive surgery; NCDB, National
Cancer Database; NHB, non-Hispanic Black; NHW,
non-Hispanic White; OR, odds ratio; SDOH, social
determinants of health; SEER, Surveillance
Epidemiology and End Results; STROBE,
Strengthening the Reporting of Observational
Studies in Epidemiology.
What do these findings mean?
• Results from this study suggest that even with private and Medicare insurance, certain
underrepresented and underprivileged minorities such as Blacks and Hispanics are still
less likely to receive standard of care for CC.
• Simply providing these patients with health insurance alone may not be enough to
reduce these disparities.
• Different minorities, such as Blacks and Hispanics, have different disparities in regard
to CC treatment.
• Additional research needs to be performed to identify factors that are preventing Blacks
and Hispanics from receiving the standard of care for CC outside of health insurance.
Introduction
Over 100,000 new cases of colon cancer (CC) will be diagnosed in 2021, with the highest inci-
dence among non-Hispanic Black (NHB) patients [1]. Overall, patients of NHB and Hispanic
race/ethnicity have a higher incidence of CC, are diagnosed with more advanced disease, and
experience worse overall survival compared to patients of non-Hispanic White (NHW) race
[1]. It has been estimated that the increase in CC mortality among Black patients may be sec-
ondary to more advanced or later stage disease at presentation [2]. This is likely also strongly
influenced by social determinants of health (SDOH), which can include but are not limited to
education level, employment, income level or poverty, and housing or homelessness [2]. Inter-
ventions focused on eliminating racial disparities in screening rates by overcoming some of
these barriers have shown improvement in, and in some cases, even elimination of regional
racial disparities in cancer outcomes [3].
Passage of the Affordable Care Act (ACA) in 2010 aimed to reduce disparities in insurance
coverage with the goal of improving overall access to healthcare, including preventative care
[4]. Following implementation of the ACA, health insurance coverage, screening rates, and the
frequency of physician visits increased for patients of NHB and Hispanic race/ethnicity [5,6].
However, despite these improvements, minority patients still face delays in cancer treatment
and are less likely to receive appropriate therapy [7–9]. It has been proposed that disparities in
care may be related to environmental, lifestyle, cultural, socioeconomic, behavioral, and bio-
logic factors as well as access to quality healthcare [10]. Ultimately, however, the intersection
between racial disparities in treatment and insurance status remains poorly understood.
The primary aim of this study was to evaluate this intersection between race/ethnicity and
insurance, specifically to determine whether racial/ethnic disparities in the receipt of CC treat-
ment potentially differ among patients with the same insurance coverage.
Methods
Data source
The National Cancer Database (NCDB), sponsored by the American College of Surgeons and
American Cancer Society, gathers data from more than 1,500 Commission on Cancer (CoC)-
accredited facilities in the US. CoC cancer registrars are trained and certified to code data
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according to rigorously established protocols. The NCDB includes data on more than 70% of
newly diagnosed cancer cases nationwide and is felt to be representative of national practice
patterns in cancer care [11]. This study was reviewed by the Institutional Review Board of the
Brody School of Medicine at East Carolina University and determined to be exempt. Results
are reported per the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guidelines [12].
Study population
Patients aged 18 years or older with a new diagnosis of stage I, II, or III adenocarcinoma of the
colon, as defined by the American Joint Commission on Cancer (AJCC), between 2006 and
2016 were identified from the NCDB. Stage was defined according to the sixth and seventh
edition of the AJCC Cancer Staging ManuaI [13,14]. Patients with a prior cancer diagnosis
were excluded. Patients were then divided into cohorts by race/ethnicity for comparison.
Patient race and ethnicity were determined from predefined NCDB data based on assignment
by a CoC registrar according to fixed categories, specifically NHW, NHB, Hispanic, and
Other.
Variables and outcomes
Clinical and demographic variables were selected a priori from the available data provided in
the NCDB participant user file. These included age, race, ethnicity, sex, primary payor, median
household income, educational attainment (number of adults in the patient’s ZIP code who
did not graduate from high school), rural/urban residence, distance traveled for care, and
Charlson/Deyo comorbidity index. Cancer-specific variables included primary tumor location,
histologic grade, and analytic stage based on the AJCC classification sixth and seventh edition.
Primary tumor location was categorized as left (splenic flexure, descending, or sigmoid), right
(cecum, ascending, hepatic flexure, or transverse), or overlapping/not otherwise specified. The
design and analysis plan for the study is shown in the Supporting information (S1 Table). The
primary outcomes of interest were (1) receipt of surgical resection; and (2) receipt of adjuvant
chemotherapy in the subgroup of eligible patients with resected stage III CC, stratified by race/
ethnicity and insurance.
Statistical analysis
Continuous variables are described by the number of nonmissing observations, mean, stan-
dard deviation, median, and 25th and 75th percentiles. Categorical variables are described
overall and by cohort with the number of patients and percentage for each category. Missing
data were considered as a separate category.
Outcomes of receipt of surgery and receipt of chemotherapy were stratified by race/ethnic-
ity and insurance and presented as unadjusted percentages. Comparisons were made using
chi-squared, 1-way ANOVA, and Kruskal–Wallis tests as appropriate. To adjust for confound-
ing and estimate the association of outcome to covariates, data were fit using multivariable
binary logistic regression models. Generalized estimating equations (GEEs) approach was
used to accommodate facility clustering assuming an exchangeable working correlation struc-
ture. Two GEE models were fit to the data: a main effects model with additive terms for race
and insurance status adjusted for additional covariates and a joint effects model with a 2-way
interaction term for race and insurance also adjusted for additional covariates. These included
age, race, sex, insurance status, income level, education, rurality, comorbidity, distance trav-
eled for care, and tumor stage. For the analysis of receipt of adjuvant chemotherapy outcome,
the GEE models also included surgical margins status and the number of lymph nodes
PLOS MEDICINE Colon cancer treatment disparities
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003842 October 25, 2021 4 / 18
resected. Parameter estimates were tested using the Z score. The standard errors, confidence
intervals (CIs), Z scores, and p-values are based on empirical standard error estimates. The
joint effects model was used to evaluate the effect of race on outcome within levels of insurance
status. Adjusted odds ratios (ORs) and 95% CIs are provided as measures of strength of associ-
ation and precision, respectively. The joint effect of race and insurance status on outcomes was
tested using the generalized score chi-squared on 12 degrees of freedom. A 2-sided p-value
<0.05 was considered statistically significant. Missing/unknown data were excluded in the
multivariable analyses. Analyses were performed with SAS statistical software (version 9.4,
SAS Institute, Cary, North Carolina, US).
Results
Demographics
Of the 908,503 patients with CC identified in the 2006 to 2016 NCDB participant user file,
353,998 patients met inclusion criteria (Fig 1). The subgroup of patients with stage III disease
assessed for receipt of adjuvant chemotherapy totaled 129,341 patients. Demographic data by
racial cohorts are demonstrated in Table 1. There were some small differences in regard to
mean age at diagnosis and sex across groups. Clinical characteristics were also somewhat dif-
ferent among the cohorts, including Charlson/Deyo comorbidity index as well as primary
tumor location (right-sided tumor; 61.1% NHW versus 59.8% NHB, p< 0.001). AJCC stage
distribution also varied among the cohorts, with approximately 28.1% stage I, 35.2% stage II,
and 36.2% stage III among NHW and 27.5% stage I, 32.7% stage II, and 39.8% stage III among
NHB (p< 0.001).
Socioeconomic differences were also observed between cohorts. Compared to NHW
patients, more NHB patients were uninsured (6.2% versus 2.1%, p< 0.001) or Medicaid
insured (9.5% versus 3.0%, p< 0.001). Similarly, more Hispanic patients were uninsured
(8.9% versus 2.1%, p< 0.001) or Medicaid insured (12.3% versus 3.0%, p< 0.001) compared
to NHW patients. More NHB patients compared to NHW patients resided in a region with
lower median income (45.1% versus 15.1% with median income <US$40,227, p< 0.001) and
lower education level (40.9% versus 16.3% residing in a ZIP code in which�17.6% did not
graduate from high school, p< 0.001). Hispanic patients were also more likely to reside in
metropolitan areas compared to NHW patients (93.7% versus 80.6%, p< 0.001).
Receipt of therapy
Among the entire cohort, 347,206 patients (98.08%) underwent surgery, with a mean time to
treatment of 16.3 days (SD 28.4) (Table 2). Patients across all racial/ethnic cohorts had similar
rates of surgery; however, NHB patients had slightly longer time to surgery compared to
NHW patients (18.1 versus 15.9 days, p< 0.001). Of the subgroup of patients with stage III CC
who underwent definitive resection, only 68.4% (N = 88,489) received adjuvant chemotherapy,
at a mean of 52 days from resection to start of treatment. When evaluated by race/ethnic
group, 67.6% of patients of NHW race received adjuvant chemotherapy compared to 70.9% of
patients of NHB race (p< 0.001). NHB patients had a slightly longer time from surgery to the
start of chemotherapy compared to NHW patients (50.1 versus 56.0 days, p< 0.001).
On unadjusted univariate regression analyses, race/ethnic groups were less likely to receive
surgery compared to patients of NHW race but were more likely to receive adjuvant chemo-
therapy compared to patients of NHW race (Table 3). All other insurance categories were
associated with lower likelihood of receipt of resection or chemotherapy compared to the pri-
vate insurance category.
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Fig 1. Flow diagram of cohort selection. PUF, participant user file.
https://doi.org/10.1371/journal.pmed.1003842.g001
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Table 1. Cohort demographics by race/ethnicity, 2006 to 2016.
Racial/ethnic group
NHW n = 261,349 NHB n = 41,511 Hispanic n = 18,835 Other n = 32,303 Overall n = 353,998 p-Value
Age at diagnosis (years) listed as mean (SD) 69.58 (12.53) 64.46 (12.04) 64.95 (12.58) 67.82 (12.68) 68.57 (12.63) p< 0.001
Insurance
Uninsured 5,503 (2.1%) 2,588 (6.2%) 1,682 (8.9%) 1,100 (3.4%) 10,873 (3.1%) p< 0.001
Medicaid 7,822 (3.0%) 3,953 (9.5%) 2,322 (12.3%) 2,082 (6.5%) 16,179 (4.6%)
Medicare 158,536 (60.7%) 19,410 (46.8%) 8,028 (42.6%) 16,600 (51.4%) 202,574 (57.2%)
Private 87,311 (33.4%) 15,107 (36.4%) 6,681 (35.5%) 12,189 (37.7%) 121,288 (34.3%)
Other government 2,177 (0.8%) 453 (1.1%) 122 (0.7%) 332 (1.0%) 3,084 (0.9%)
Sex p< 0.001
Female 135,924 (52.0%) 23,212 (55.9%) 9,251 (49.1%) 16,957 (54.5%) 185,344 (52.4%)
Male 125,425 (48.0%) 18,299 (44.1%) 9,584 (50.9%) 15,346 (47.5%) 168,654 (47.6%)
Median household income p< 0.001
Less than UAU : PleasecheckandconfirmifthecurrencyðUSÞusedthroughoutthepaperiscorrect;andamendifnecessary:S$40,227 39,330 (15.1%) 18,699 (45.1%) 5,110 (27.1%) 5,235 (16.2%) 68,374 (19.3%)
US$40,228 to US$50,353 59,548 (22.8%) 8,359 (20.1%) 4,361 (23.2%) 6,542 (20.3%) 78,810 (22.3%)
US$50,354 to US$63,332 63,282 (24.2%) 6,326 (15.2%) 4,412 (23.4%) 7,418 (23.0%) 81,438 (23.0%)
US$63,333+ 95,441 (36.5%) 7,445 (17.9%) 4,740 (25.2%) 12,747 (39.5%) 120,373 (34.0%)
Not available 3,748 (1.4%) 682 (1.6%) 212 (1.1%) 361 (1.1%) 5,003 (1.4%)
% did not graduate from HS p< 0.001
Less than 6.3% 68,457 (26.2%) 3,376 (8.1%) 1,727 (9.2%) 819 (25.4%) 81,753 (23.1%)
6.3% to 10.8% 78,959 (30.2%) 7,459 (18.0%) 2,935 (15.6%) 9,103 (28.2%) 98,456 (27.8%)
10.9% to 17.5% 68,057 (26.0%) 13,081 (31.5%) 3,896 (20.7%) 8,091 (25.1%) 93,125 (26.3%)
17.6% or more 42,683 (16.3%) 16,982 (40.9%) 10,082 (53.5%) 6,607 (20.5%) 76,354 (421.6%)
Not available 3,193 (1.2%) 613 (1.5%) 195 (1.0%) 309 (1.0%) 4,310 (1.2%)
Rurality p< 0.001
Metro 210,691 (80.6%) 36,998 (89.1%) 17,654 (93.7%) 27,341 (84.6%) 292,684 (82.7%)
Urban 38,396 (14.7%) 3,369 (8.1%) 784 (4.2%) 3,610 (11.2%) 46,159 (13.0%)
Rural 5,445 (2.1%) 454 (1.1%) 48 (0.3%) 679 (2.1%) 6,626 (1.9%)
Not available 6,817 (2.6%) 690 (1.7%) 349 (1.9%) 673 (2.1%) 8,529 (2.4%)
Distance traveled for care p< 0.001
Mean (SD) 23.25 (93.92) 14.68 (60.03) 16.87 (75.84) 21.99 (110.68) 21.79 (91.47)
25th to 75th 3.90 to 18.90 3.00 to 12.20 3.10 to 11.90 3.50 to 15.40 3.70 to 17.40
Median 8.30 6.20 6.20 7.20 7.80
Charlson/Deyo comorbidity index p< 0.001
0 175,197 (67.0%) 27,342 (65.9%) 12,857 (68.3%) 22,504 (69.7%) 237,900 (67.2%)
1 58,370 (22.3%) 9,819 (23.7%) 4,357 (23.1%) 6,870 (21.3%) 79,416 (22.4%)
2 18,498 (7.1%) 2,802 (6.8%) 1,042 (5.5%) 2,010 (6.2%) 24,352 (6.9%)
3 or more 9,284 (3.6%) 1,548 (3.7%) 579 (3.1%) 919 (2.8%) 12,330 (3.5%)
Facility type p< 0.001
Community 35,265 (13.5%) 3,899 (9.4%) 1,926 (10.2%) 3,879 (12.0%) 44,969 (12.7%)
Comprehensive 127,134 (48.7%) 15,706 (37.8%) 7,960 (42.3%) 13,881 (43.0%) 164,681 (46.5%)
Academic 61,016 (23.4%) 15,318 (36.9%) 6,078 (32.3%) 9,671 (29.9%) 92,083 (26.0%)
Integrated network 37,934 (14.5%) 6,588 (15.9%) 2,871 (15.2%) 4,872 (15.1%) 52,265 (14.8%)
Primary site p< 0.001
Right 159,760 (61.1%) 24,822 (59.8%) 10,354 (55.0%) 17,689 (54.8%) 212,625 (60.1%)
Left 93,789 (35.9%) 15,198 (36.6%) 7,892 (41.9%) 13,532 (41.9%) 130,411 (36.8%)
Overlapping/NOS 7,800 (3.0%) 1,491 (3.6%) 589 (3.1%) 1,082 (3.4%) 10,962 (3.1%)
Grade p< 0.001
(Continued)
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Multivariable logistic regression: Main effects
NHB and Hispanic race/ethnicity were independently associated with decreased odds of
undergoing surgical resection compared to NHW race [OR 0.66, 95% CI 0.61 to 0.72 (NHB);
OR 0.76, 95% CI 0.67 to 0.85 (Hispanic)] (Fig 2). Other factors independently associated with
decreased odds of resection included Medicaid insurance (OR 0.54, 95% CI 0.47 to 0.62) and
higher Charlson/Deyo comorbidity index (OR 0.73, 95% CI 0.65 to 0.81, score of 3 or more
versus 0). Compared to private insurance, patients with Medicare insurance had higher odds
of undergoing surgical resection (OR 1.19, 95% CI 1.11 to 1.28) (Table 4).
Table 1. (Continued)
Racial/ethnic group
NHW n = 261,349 NHB n = 41,511 Hispanic n = 18,835 Other n = 32,303 Overall n = 353,998 p-Value
1 27,892 (10.7%) 4,694 (11.3%) 2,037 (10.8%) 3,428 (10.6%) 38,051 (10.7%)
2 171,698 (65.7%) 28,747 (69.2%) 12,583 (66.8%) 21,720 (67.2%) 234,748 (66.3%)
3 42,506 (16.3%) 5,009 (12.1%) 2,822 (15.0%) 4,953 (15.3%) 55,290 (15.6%)
4 7,074 (2.7%) 662 (1.6%) 394 (2.1%) 568 (1.8%) 8,698 (2.5%)
Not available 12,179 (4.7%) 2,399 (5.8%) 999 (5.3%) 1,634 (5.1%) 17,211 (4.9%)
AJCC stage p< 0.001
I 73,420 (28.1%) 11,410 (27.5%) 4,675 (24.8%) 8,861 (27.5%) 98,366 (27.8%)
II 93,215 (35.7%) 13,567 (32.7%) 6,514 (34.6%) 11,221 (34.7%) 124,517 (35.2%)
III 94,714 (36.2%) 16,534 (39.8%) 7,646 (40.6%) 12,221 (37.8%) 131,115 (37.0%)
AAU : TheabbreviationslistsofTables1   6havebeenupdated:Pleaseverifythatallentriesarecorrect:JCC, Am rican Jo nt Committee on Cancer; HS, high school; NHB, non-Hispanic Black; NHW, non-Hispanic White; NOS, not otherwise specified; SD, standard
deviation.
https://doi.org/10.1371/journal.pmed.1003842.t001
Table 2. Receipt of treatment by insurance and race/ethnicity.
Cohort Surgery Chemotherapy
No n (%) Yes n (%) Treatment started, days
from Dx [mean (SD)]


































































































51.3 (34.7) p< 0.001
Dx, diagnosis; NHB, non-Hispanic Black; NHW, non-Hispanic White; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003842.t002
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Table 3. Unadjusted odds of undergoing surgical resection or receiving adjuvant chemotherapy.
Surgical resection, stage I to III (N = 353,998)
Factor OR 95% CI p-Value
Insurance status
Private Ref — —
Medicare 0.42 0.51 to 0.57 <0.001
Other government 0.54 0.34 to 0.51 <0.001
Medicaid 0.51 0.46 to 0.56 <0.001
Uninsured 0.55 0.49 to 0.63 <0.001
Race/ethnicity
NHW Ref — —
NHB 0.69 0.65 to 0.73 <0.001
Hispanic 0.78 0.71 to 0.85 <0.001
Other 0.91 0.82 to 1.02 0.10
Age 0.96 0.96 to 0.96 <0.001
Income
Less than US$40,227 Ref — —
US$40,227 to US$50,353 1.14 1.07 to 1.22 <0.001
US$50,353 to US$63,332 1.21 1.13 to 1.28 <0.001
US$63,333+ 1.28 1.21 to 1.36 <0.001
Sex
Male Ref — —
Female 0.95 0.91 to 0.99 0.18
Rurality
Metro Ref — —
Urban 1.04 0.97 to 1.10 0.26
Rural 1.40 1.16 to 1.67 <0.001
Charlson/Deyo comorbidity index
0 Ref — —
1 1.07 1.02 to 1.13 0.01
2 0.78 0.73 to 0.85 <0.001
3 or more 0.58 0.53 to 0.64 <0.001
Stage
1 Ref — —
2 2.81 2.67 to 2.95 <0.001
3 3.83 3.62 to 4.05 <0.001
Adjuvant chemotherapy, stage III (N = 129,341)
Insurance status
Private Ref — —
Medicare 0.24 0.24 to 0.25 <0.001
Other government 0.56 0.50 to 0.64 <0.001
Medicaid 0.62 0.59 to 0.66 <0.001
Uninsured 0.71 0.66 to 0.76 <0.001
Race/ethnicity
NHW Ref — —
NHB 1.20 1.16 to 1.24 <0.001
Hispanic 1.42 1.35 to 1.50 <0.001
Other 1.38 1.31 to 1.46 <0.001
Age 0.92 0.92 to 0.92 <0.001
(Continued)
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In regard to receipt of adjuvant therapy in resected patients, NHB patients had a signifi-
cantly decreased likelihood of receiving adjuvant chemotherapy [OR 0.83, 95% CI 0.78 to
0.87], but Hispanic patients actually had a higher likelihood of receiving adjuvant therapy [OR
1.20, 95% CI 1.09 to 1.33]. Compared to patients with private insurance, patients with Medic-
aid or no insurance also had a significantly decreased likelihood of receiving adjuvant chemo-
therapy compared to those with private insurance [OR 0.55, 95% CI 0.50 to 0.61(Medicaid),
OR 46, 95% CI 0.41 to 0.53 (no insurance)], but those with Medicare did not (OR 1.02, 95% CI
0.98 to 1.08). (Table 4).
Multivariable logistic regression: Joint effects
NHB and Hispanic patients with Medicare insurance had lower odds of receiving surgery
compared to NHW patients with Medicare insurance [OR 0.59, 95% CI 0.53 to 0.66 (NHB);
OR 0.71, 95% CI 0.61 to 0.84 (Hispanic)] (Table 5). Similar findings were also observed
among NHB and Hispanic patients with private insurance compared to NHW patients with
private insurance [OR 0.76, 95% CI 0.63 to 0.91 (NHB); OR 0.72, 95% CI 0.56 to 0.92 (His-
panic)]. The odds of receiving adjuvant chemotherapy was also lower for NHB compared to
NHW among patients with Medicaid (OR 0.81, 95% CI 0.66 to 0.98), Medicare (OR 0.86, 95%
CI 0.80 to 0.91), private insurance (OR 0.77, 95% CI 0.68 to 0.87), and other government
insurance (OR 0.59, 95% CI 0.35 to 1.00). (Table 6) Hispanic patients actually had a higher
Table 3. (Continued)
Surgical resection, stage I to III (N = 353,998)
Factor OR 95% CI p-Value
Income
Less than US$40,227 Ref — —
US$40,227 to US$50,353 1.06 1.03 to 1.10 <0.001
US$50,353 to US$63,332 1.08 1.03 to 1.10 <0.001
US$63,333+ 1.13 1.09 to 1.16 <0.001
Sex
Male Ref — —
Female 0.83 0.0.81 to 0.85 <0.001
Rurality
Metro Ref — —
Urban 1.06 1.03 to 1.10 <0.001
Rural 1.04 0.96 to 1.12 0.35
Charlson/Deyo comorbidity index
0 Ref — —
1 0.68 0.67 to 0.70 <0.001
2 0.46 0.44 to 0.48 <0.001
3 or more 0.33 0.31 to 0.35 <0.001
Margin positive
Negative Ref — —
Positive 0.77 0.74 to 0.80 <0.001
Number of lymph nodes resected
�12 Ref — —
�12 1.52 1.48 to 1.56 <0.001
CI, confidence interval; NHB, non-Hispanic Black; NHW, non-Hispanic White; OR, odds ratio; Ref, reference.
https://doi.org/10.1371/journal.pmed.1003842.t003
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odds of receiving adjuvant chemotherapy compared to NHW patients in both the Medicare
(OR 1.33, 95% CI 1.17 to 1.52) and Medicaid (OR 1.38, 95% CI 1.02 to 1.87) cohorts and were
similar to NHW in the other insurance groups (Table 6).
Discussion
Despite recent advancements in CC screening, diagnosis, and treatment, patients of NHB and
Hispanic race/ethnicity continue to experience worse long-term outcomes. In this large,
national study of over 300,000 patients with stage I, II, or III CC diagnosed at CoC hospitals,
NHB and Hispanic patients had lower odds of undergoing curative-intent resection, and NHB
had lower odds of receiving adjuvant chemotherapy, even in the setting of equivalent health
insurance. Importantly, NHB patients had higher rates of no insurance or Medicaid insurance,
lower median household income, and more often resided in a ZIP code with less educational
attainment. Even after adjusting for these socioeconomic differences, NHB had lower odds of
undergoing resection or receiving adjuvant chemotherapy. Further, these differences persisted
when comparing racial cohorts with the same health insurance status, suggesting that adequate
insurance coverage is not associated with mitigated racial disparities in cancer care delivery.
Across all stages of diagnosis, Black patients are less likely to receive treatment for colorectal
cancer [15]. Prior studies of the Surveillance Epidemiology and End Results (SEER) registry
have demonstrated that Black patients have lower odds of undergoing surgery for colorectal
cancer [15–17]. Disparities in receipt of adjuvant chemotherapy for colorectal cancer and
receipt of radiation for rectal cancer for Black and Hispanic patients have also been described
based on SEER data [7,15–17]. A recently published study of California state registry data
from 2000 to 2012 found that Black patients with metastatic colorectal cancer were less likely
Fig 2. Adjusted odds of receiving surgery or chemotherapy by insurance and race/ethnicity. Data points represent
OR, and bars represent 95% CI. Regression model also included the following covariates: age, sex, income, Charlson/
Deyo comorbidity index, stage, grade, and rurality. For the chemotherapy group, margin status and number of nodes
resected were also included. CI, confidence interval; NHB, non-Hispanic Black; NHW, non-Hispanic White; OR, odds
ratio.
https://doi.org/10.1371/journal.pmed.1003842.g002
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Table 4. Adjusted odds of undergoing surgical resection or receiving adjuvant chemotherapy.
Surgical resection, stage I to III (N = 353,998)
Factor OR 95% CI p-Value
Insurance status
Private Ref — —
Medicare 1.19 1.11 to 1.28 <0.001
Other government 0.55 0.44 to 0.70 <0.001
Medicaid 0.54 0.47 to 0.62 <0.001
Uninsured 0.43 0.37 to 0.51 <0.001
Race/ethnicity
NHW Ref — —
NHB 0.66 0.61 to 0.72 <0.001
Hispanic 0.76 0.67 to 0.85 <0.001
Other 0.87 0.79 to 0.97 0.002
Age 0.94 0.94 to 0.95 <0.001
Income
Less than US$40,227 Ref — —
US$40,227 to US$50,353 1.05 0.96 to 1.14 0.29
US$50,353 to US$63,332 1.09 1.00 to 1.19 0.059
US$63,333+ 1.22 1.11 to 1.34 <0.001
Sex
Male Ref — —
Female 1.04 0.98 to 1.09 0.18
Rurality
Metro Ref — —
Urban 1.01 0.93 to 1.10 0.79
Rural 1.53 1.23 to 1.90 <0.001
Charlson/Deyo comorbidity index
0 Ref — —
1 1.19 1.11 to 1.26 <0.001
2 0.95 0.87 to 1.04 0.27
3 or more 0.73 0.65 to 0.81 <0.001
Stage
1 Ref — —
2 2.91 2.69 to 3.15 <0.001
3 3.88 3.58 to 4.21 <0.001
Adjuvant chemotherapy, stage III (N = 129,341)
Insurance status
Private Ref — —
Medicare 1.02 0.98 to 1.08 0.26
Other government 0.83 0.67 to 1.03 0.084
Medicaid 0.55 0.50 to 0.61 <0.001
Uninsured 0.46 0.41 to 0.53 <0.001
Race/ethnicity
NHW Ref — —
NHB 0.83 0.78 to 0.87 <0.001
Hispanic 1.20 1.09 to 1.33 <0.001
Other 0.97 0.91 to 1.04 0.43
Age 0.90 0.90 to 0.91 <0.001
(Continued)
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to receive chemotherapy or to undergo hepatic metastectomy [18]. A recent study of patients
with gastrointestinal cancers (including colorectal cancer) identified in the 2004 to 2015
NCDB found that a disparity in the receipt of surgery had significant influence on survival dis-
parity for Black compared to White patients [9]. In addition, Black patients are less likely to
enroll in clinical trials and are less likely to discuss or consider trial enrollment [19,20]. Black
patients are also less likely to receive posttreatment surveillance testing [21]. The aggregate dis-
parity in receipt of care for Black patients appears to correlate with the ultimate disparity in
survival outcomes for these same patients [10,21,22].
It is also well established that minority race/ethnicity patients are more frequently underin-
sured. Nationally, Black and Hispanic patients have lower rates of private insurance and con-
currently higher rates of public or no insurance compared to White patients [23]. Uninsured
rates are particularly high among rural residents of racial/ethnic minority and correlate with
self-reported poor health [24]. Inadequate insurance not only limits receipt of care but may
also even impact the potential therapeutic benefit of experimental therapy in the context of
clinical trials. Pooled data from clinical trials found that patients with Medicaid insurance or
with no insurance received less benefit from experimental therapy in the context of a clinical
trial when compared to patients with Medicare or private insurance [25]. Not surprisingly,
those with Medicaid or no insurance included higher percentages of minority race/ethnicity.
Table 4. (Continued)
Surgical resection, stage I to III (N = 353,998)
Factor OR 95% CI p-Value
Income
Less than US$40,227 Ref — —
US$40,227 to US$50,353 1.07 1.01 to 1.12 0.015
US$50,353 to US$63,332 1.17 1.11 to 1.23 <0.001
US$63,333+ 1.22 1.16 to 1.29 <0.001
Sex
Male Ref — —
Female 1.01 0.98 to 1.04 0.39
Rurality
Metro Ref — —
Urban 0.97 0.92 to 1.03 0.35
Rural 0.94 0.84 to 1.04 0.24
Charlson/Deyo comorbidity index
0 Ref — —
1 0.85 0.82 to 0.88 <0.001
2 0.64 0.60 to 0.67 <0.001
3 or more 0.47 0.44 to 0.51 <0.001
Margin positive
Negative Ref — —
Positive 0.77 0.72 to 0.81 <0.001
Number of lymph nodes resected
�12 Ref — —
�12 1.28 1.22 to 1.34 <0.001
CI, confidence interval; NHB, non-Hispanic Black; NHW, non-Hispanic White; OR, odds ratio; Ref, reference.
https://doi.org/10.1371/journal.pmed.1003842.t004
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Insurance coverage disparities in general are associated with inadequate CC care and sur-
vival and represent a key contributing factor to outcome disparities for patients of minority
race and ethnicity [10,26]. A 2016 study on the Massachusetts health insurance reform from
2006 identified improved colorectal cancer resection rates in the state compared to 3 control
states without similar health insurance reforms [27]. Although an association with racial treat-
ment disparities was not specifically examined, these findings, along with other studies
Table 5. Effect modification of insurance on race/ethnicity and surgical resection.
Insurance Race/ethnicity Surgical resection
OR 95% CI p-Value E-Value
Uninsured NHW Ref
NHB 0.91 0.64 to 1.28 0.58 1.28
Hispanic 0.95 0.6 to 1.50 0.81 1.2
Medicaid NHW Ref
NHB 0.94 0.73 to 1.20 0.60 1.22
Hispanic 1.27 0.91 to 1.77 0.15 1.51
Medicare NHW Ref
NHB 0.59 0.53 to 0.66 <0.001 1.92
Hispanic 0.71 0.61 to 0.84 <0.001 1.65
Private NHW Ref
NHB 0.76 0.63 to 0.91 0.004 1.55
Hispanic 0.72 0.56 to 0.92 0.009 1.64
Other government NHW Ref
NHB 0.98 0.49 to 1.95 0.95 1.2
Hispanic 0.44 0.16 to 1.21 0.11 2.39
CI, confidence interval; NHB, non-Hispanic Black; NHW, non-Hispanic White; OR, odds ratio; Ref, reference.
https://doi.org/10.1371/journal.pmed.1003842.t005
Table 6. Effect modification of insurance on race/ethnicity and adjuvant chemotherapy.
Insurance Race/ethnicity Adjuvant chemotherapy
OR 95% CI p-Value E-value
Uninsured NHW Ref
NHB 0.96 0.72 to 1.29 0.81 1.15
Hispanic 1.07 0.76 to 1.50 0.70 1.22
Medicaid NHW Ref
NHB 0.81 0.66 to 0.98 0.031 1.47
Hispanic 1.38 1.02 to 1.87 0.035 1.63
Medicare NHW Ref
NHB 0.86 0.80 to 0.91 <0.001 1.39
Hispanic 1.33 1.17 to 1.52 <0.001 1.58
Private NHW Ref
NHB 0.77 0.68 to 0.87 <0.001 1.54
Hispanic 0.96 0.81 to 1.13 0.64 1.16
Other government NHW Ref
NHB 0.59 0.35 to 1.00 0.05 1.92
Hispanic 0.96 0.81 to 1.13 0.64 1.16
CI, confidence interval; NHB, non-Hispanic Black; NHW, non-Hispanic White; OR, odds ratio; Ref, reference.
https://doi.org/10.1371/journal.pmed.1003842.t006
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investigating the impact of the ACA, indicate that insurance coverage plays an important role
in the observed treatment and survival disparities in colorectal cancer [28,29].
However, insurance is not the only factor. Evidence indicates that disparities in long-term
outcomes experienced by Black patients are multilevel in etiology and may include limited
access to screening, mistrust of physicians, socioeconomic barriers including financial limita-
tions, and receipt of quality care [3,30]. This study sought specifically to investigate the inter-
section of race/ethnicity and insurance with cancer treatment disparities. To our knowledge,
the only prior similar analysis on cancer treatment utilized the SEER dataset from 1990 to
2010 and found that Black patients had lower odds of receipt of adjuvant chemotherapy
regardless of insurance status [7]. However, there are significant limitations in the assessment
of chemotherapy use within the SEER dataset. A 2016 study on disparities in minimally inva-
sive surgery (MIS) approach for colorectal surgery did find persistent Black disparities after
stratification by private versus public insurance; however, indications for surgery included
benign colorectal and diverticular disease. [31]. While other studies have attempted to adjust
for either insurance or race/ethnicity as a covariate, this intersection of insurance and race/eth-
nicity on cancer treatment disparities has not been directly explored. In this analysis, NHB
and Hispanic patients had a persistently lower odds of surgical resection. Interestingly, how-
ever, although NHB who underwent resection had lower odds of receiving adjuvant chemo-
therapy, Hispanic patients did not even in the setting of equivalent health insurance status.
This was a surprising finding and suggests that independent factors may play a role in explain-
ing disparities among different races as well as different treatment regimens even among
underrepresented and underprivileged minorities.
The use of data obtained from the NCDB merits consideration of several limitations
[32]. First, continuity or disruption of insurance coverage cannot be assessed within
NCDB; therefore, the association between outcomes and interrupted coverage or disrup-
tion of preexisting coverage remains unknown. Second, specific details on chemotherapy
agents or dosing are not available to assess for standard of care treatment. Third, although
the NCDB is based on rigorous comprehensive data collection, the dataset lacks informa-
tion regarding specific SDOH, thereby limiting a more comprehensive analysis of other
social factors likely to affect healthcare access. In addition, the available socioeconomic var-
iables are based on median values from the ZIP code of residence and are not specific to
the individual patient. Furthermore, many potentially confounding factors that may help
explain findings in this study are not collected within the NCDB. Fifth, reasons for why a
specific treatment was not readily available within the dataset. Finally, the NCBD is not
inclusive of all cancer care facilities, hence the data presented may not be generalizable to
non CoC-accredited facilities.
Conclusions
Patients with Medicaid insurance coverage or lack of insurance and patients of minority race/
ethnicity, especially NHB, are less likely to undergo surgical resection or receive adjuvant che-
motherapy. Black and Hispanic patients with equivalent insurance coverage still experience
lower odds of surgical resection, and Black patients still experience lower odds of receipt of
adjuvant chemotherapy. Changes in health policy must recognize that provision of insurance
alone is not associated with improved disparities in cancer care among minority populations
and that different minority populations may have different challenges precluding receipt of the
standard of care. Comprehensive study of other SDOH such as poverty, literacy, and rurality
of residence, as well as policy change addressing these factors, is needed to ensure equity in
cancer patient care for patients of all races.
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